<p style="text-align: justify;">Long-term Safety and Efficacy Study of Ferriprox® for the Treatment of<br />Transfusional Iron Overload in Patients with Sickle Cell Disease<br />or Other Anemias</p> Read more about Long-term Safety and Efficacy Study of Ferriprox® for the Treatment ofTransfusional Iron Overload in Patients with Sickle Cell Diseaseor Other Anemias
"A Phase 3B, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety ofAbatacept SC in Combination with Methotrexate Compared to Methotrexate Monotherapy in Achieving Clinical Remission in Adults with Early Rheumatoid Arthritis who are Methotrexate Naive" Read more about "A Phase 3B, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety ofAbatacept SC in Combination with Methotrexate Compared to Methotrexate Monotherapy in Achieving Clinical Remission in Adults with Early Rheumatoid Arthritis who are Methotrexate Naive"
A phase IIIb, open, multi-country, controlled, randomized study to demonstrate the immunogenicity and safety of GSK Biological meningococcal conjugate vaccine, MenACWYTT (GSK134612) in healthy infants, given on a 3+1 primary and booster (2, 4, 6 and 15-18 months of age), a 1+1 primary and booster (6 and 15-18 months of age), or as a single dose at 15-18 months of age Read more about A phase IIIb, open, multi-country, controlled, randomized study to demonstrate the immunogenicity and safety of GSK Biological meningococcal conjugate vaccine, MenACWYTT (GSK134612) in healthy infants, given on a 3+1 primary and booster (2, 4, 6 and 15-18 months of age), a 1+1 primary and booster (6 and 15-18 months of age), or as a single dose at 15-18 months of age
An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes With ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I) Read more about An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes With ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)
A Multicenter, Open-label, Single-arm Study of a Pertuzumab in Combination With Trastuzumab and a Taxane in First Line Treatment of Patients With HER2- Positive Advanced (Metastatic or Locally Recurrent) Breast Cancer Read more about A Multicenter, Open-label, Single-arm Study of a Pertuzumab in Combination With Trastuzumab and a Taxane in First Line Treatment of Patients With HER2- Positive Advanced (Metastatic or Locally Recurrent) Breast Cancer
The Efficacy and Safety of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias Read more about The Efficacy and Safety of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias
A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS - Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus Patients Intervention Study) Read more about A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS - Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus Patients Intervention Study)
"An Open-Label, Multinational, Multicenter, Phase IIIB Study With Subcutaneus Administration Of Trastuzumab In Patient With Her2-Positive Early Breast Cancer To Evaluate Patient Satisfaction" Read more about "An Open-Label, Multinational, Multicenter, Phase IIIB Study With Subcutaneus Administration Of Trastuzumab In Patient With Her2-Positive Early Breast Cancer To Evaluate Patient Satisfaction"
An Open-lable, Multicenter, expanded access study of INC424 for patients with primary myelofibrosis (PMF) or post polycythemia myelofibrosis (PPV MF) or post-essential thrombocythemia myelofibrosis (PET-MF). Read more about An Open-lable, Multicenter, expanded access study of INC424 for patients with primary myelofibrosis (PMF) or post polycythemia myelofibrosis (PPV MF) or post-essential thrombocythemia myelofibrosis (PET-MF).
"Phase 3, Open/Label Study to evaluate the safety and efficacy of TMC 435 plus Pegylated Interferon alfa-2a and Ripavirin administrated for 12 weeks in treatment-naïve Subjects with Chronic genotype 1 or genotype 4 HCV infection" Read more about "Phase 3, Open/Label Study to evaluate the safety and efficacy of TMC 435 plus Pegylated Interferon alfa-2a and Ripavirin administrated for 12 weeks in treatment-naïve Subjects with Chronic genotype 1 or genotype 4 HCV infection"
